A benzenesulfonamide derivative with vasodilatory activity. Udenafil selectively inhibits phosphodiesterase type 5 (PDE5), thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis; inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection. This agent does not significantly inhibit the PDE11 isozyme; PDE11 inhibition may be associated with significant myalgia.
(Other name for: fluoxymesterone)
(Other name for: sevoflurane)
(Other name for: remifentanil hydrochloride)
(Other name for: povidone-iodine)
ULvWF multimer-targeting agent ARC1779
An optimized, second-generation, PEGylated aptamer with antithrombotic property. ULvWF multimer-targeting agent ARC1779 blocks the binding of von Willebrand factor (vWF), via the A1 domain, and ultra-large vWF multimers to platelets, as well as interfering with the binding of platelet receptor glycoprotein Ib, thus reducing platelet adhesion, aggregation and thrombus growth in arterial beds. Unlike other antiplatelet agents, this aptamer can be readily reversed by binding to a complementary sequence of oligonucleotides, and may therefore offer potential therapeutic benefit in surgery.
umbilical cord blood-derived mesenchymal stem cells
Multipotent stem cells of mesenchymal origin isolated from umbilical cord blood. Umbilical cord blood-derived mesenchymal stem cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells.
(Other name for: ampicillin sodium/sulbactam sodium)
(Other name for: theophylline)
A 0.1% topical formulation of uracil used to potentially lower the incidence of hand-foot syndrome (HFS) (or palmar-plantar erythrodysesthesia) during 5-fluorouracil (5-FU) or 5-FU prodrug capecitabine chemotherapy. Upon local administration of uracil ointment to the skin, uracil competes with capecitabine or 5-FU as substrates for the activating enzyme thymidine phosphorylase and the metabolizing enzyme dihydropyrimidine dehydrogenase. This may prevent the production of 5-FU as well as the breakdown of 5-FU into the toxic metabolites locally. As the 5-FU metabolites are responsible for the presentation of HFS, inhibiting their formation may prevent this adverse effect. By applying a high concentration of uracil locally, the skin toxicities of 5-FU may be countered while preserving the systemic anti-cancer activity of the 5FU.
A humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes; its ligand has been found to play an important role in the regulation of immune responses.
A nucleoside consisting of uracil and D-ribose and a component of RNA. Uridine has been studied as a rescue agent to reduce the toxicities associated with 5-fluorouracil (5-FU), thereby allowing the administration of higher doses of 5-FU in chemotherapy regimens.
URLC10 peptide/Montanide ISA51 vaccine
A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown.
URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine
A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth.
urokinase-derived peptide A6
An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.
(Other name for: methylene blue)
(Other name for: alfuzosin hydrochloride)
(Other name for: ursodiol)
(Other name for: amoxicillin)
(Other name for: methoxsalen)
(Other name for: autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine)